Why us?  Why us? please click dropdown
4.8/5 out of 3,500+ reviews
Regulated: CQC Registered | 1-5796078466
  • Verified Content: Approved by the Women’s Health Clinic Clinical Team.
  • Educational Use: This is not a substitute for professional medical advice, diagnosis, or treatment.
  • Clinical Assessment: Individual suitability is determined by a clinician; results may vary.
  • MEDICAL EMERGENCY:

    If you need urgent help, use NHS 111. For a life-threatening emergency, call 999.

 Author  Find more about the author
Dr Farzana Khan

Dr Farzana Khan

Verified

Dr Farzana Khan qualified as an MD from the University of Copenhagen in 2003. She has worked in dermatology and obstetrics & gynaecology across the North of England and completed her MRCGP (CCT, 2013) and the Diploma of the Faculty of Sexual & Reproductive Health (2013). Her clinical focus is vaginal health—including dryness/GSM, sexual function concerns, lichen sclerosus, and comfort or volume changes. She offers careful assessment, discusses medical and conservative options first, and considers selected regenerative or aesthetic treatments where appropriate. Dr Farzana also trains clinicians as a KOL/Trainer with Neauvia, Asclepion Laser, and RegenLab (since 2023). Ongoing CPD includes IMCAS, CCR, ACE and expert training in women’s intimate fillers, PRP, and polynucleotide injectables. Her approach is simple: clear explanations, realistic expectations, and shared decision-making. Authored and medically reviewed by Dr Farzana Khan.

MD MRCGP DFFP
Was this answer helpful?
Rate Dr Farzana's explanation
Dryness & GSM faq

How much do treatments for dryness cost and what’s included?

How much do treatments for dryness cost and what’s included? Costs vary by pathway and whether you need foundations (moisturiser, lubricants), local vaginal oestrogen or DHEA, pelvic floor physio, and optional procedures (laser/radiofrequency or injectables like PRP/polynucleotides). Most plans start with an assessment, conservative care and review; procedures, if needed, are typically packaged with follow-up. See our pricing page for itemised inclusions. Educational only. Results vary. Not a cure.

Clinical Context

Who may keep costs lowest? People whose main limiter is vestibular sting/micro-tears and who nail basics: schedule a vaginal moisturiser 2–4 nights weekly, choose a compatible lubricant (silicone-based often gives the longest glide for dyspareunia), and apply creams at the vestibule as well as internally. Many reach comfort without procedures.

Who might budget for add-ons? Those with persistent symptoms after a high-quality foundation + local therapy phase, or mixed GSM features (dryness plus urinary urgency/frequency). Some will consider a short series of energy-based sessions or injectables targeted to symptomatic points; plan for review at 6–12 weeks before deciding on maintenance.

Next steps to plan spend intelligently. Start with the strongest-evidence steps; give them time to work; and use reviews to decide whether to add, switch, or pause. Our pathway pages show how we stage care and the pricing/inclusions so you can budget confidently.

Evidence-Based Approaches

First-line care & self-help (UK): The NHS outlines causes, self-care and when to seek help for vaginal dryness, including moisturiser/lubricant principles and red flags.

Guidelines: The NICE Menopause Guideline (NG23) recommends offering vaginal moisturisers and lubricants and considering low-dose local vaginal oestrogen when GSM affects quality of life; local therapy can be used with or without HRT.

Effectiveness benchmarks: Systematic reviews in the Cochrane Library show local vaginal oestrogens improve dryness, soreness, dyspareunia and vaginal pH versus placebo, helping set realistic expectations and review timing.

Pathophysiology & clinical nuance: Peer-reviewed overviews indexed on PubMed explain GSM mechanisms (thinner epithelium, raised pH, reduced lactobacilli), supporting a foundation-first approach before higher-cost adjuncts.

Regulatory/safety context: UK information on device intended use, vigilance and safety reporting is provided by the national regulator; see the MHRA medical devices pages. ® belongs to its owner.